ATRIA-CKD
This study uses “real world” data to study the efficacy and safety of atrial fibrillation therapies in patients with chronic kidney disease. This study is evaluating ~250,000 patients with incident atrial fibrillation, with and without CKD, to evavaluate adverse effects of commonly used atrial fibrillation therapies and procedures. Further, the study will evaluate whether successful use of atrial fibrillation therapies and procedures reduces rates of stroke, progression of kidney disease, heart failure and death.